Upadacitinib superior to dupilumab in Phase III head-to-head study in adults with atopic dermatitis
In the Heads Up study of adults with moderate to severe atopic dermatitis, an improvement of at least 75% in Eczema Area Severity Index (EASI 75) at week 16 was achieved in 71% of patients treated with upadacitinib and 61% of those treated with dupilumab (p=0.006).
Source:
Biospace Inc.